The impact of foreign exchange on international revenue for the first one fourth of 2012 had not been material. Combined U.S. Neulasta and NEUPOGEN sales elevated 13 % to $1,053 million in the first quarter of 2012 versus $930 million in the initial quarter of 2011, driven primarily by a rise in the average net sales price and, to a lesser extent, an increase in Neulasta device demand. Mixed Neulasta and NEUPOGEN worldwide sales decreased 4 % to $291 million in the first quarter of 2012 versus $302 million in the first quarter of 2011, because of a decrease in the average net sales cost primarily.Alvaro Pascual-Leone, MD, PhD, Director of BIDMC's Berenson-Allen Middle for non-invasive Brain Stimulation, can serve seeing that Co-Principal Investigator of the two-season $525,824 grant, with Dylan Edwards together, PhD, of the Burke Medical Analysis Institute/Weill Cornell Medical University. Mar Cortes, MD, is a crucial investigator overseeing the process implementation and bridging both research sties at BIDMC and Burke. Related StoriesLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. KlegermanAdvances entirely mount human brain imaging: an interview with Patrick Myles, President, Huron Digital PathologyInner ear harm human brain warnings from nerve cells Spinal Associative Stimulation is a non-invasive therapy that combines transcranial magnetic stimulation and peripheral nerve stimulation to greatly help bolster rehabilitation in individuals with incomplete spinal-cord injuries.